GSK
NYSE:GSKPharmaLondon, United Kingdom · Est. 2000 · 70,000 employees
Global biopharma company uniting science, technology, and talent.
71
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
68
Indications↗
Distinct diseases across all programs
3,814
Clinical Trials↗
All sponsored trials (all statuses)
23
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
71 drugs in development
Approved1
Phase 328
Phase 222
Phase 126
Preclinical14
By Therapeutic Area
top 6
Infectious Disease
2630%
Oncology
2225%
Respiratory
78%
Immunology
67%
Nephrology
33%
Cardiovascular
22%
R&D Momentum
100/100
Pipeline Velocity
84/100
Trial Completion Rate
90/100
Pipeline Concentration
20/100
Pipeline Freshness
68/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 10, 2026
Recruiting
A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of an mRNA-based Seasonal Influenza Vaccine, in Adults 18-64 Years of Age
Oct 10, 2026
Completed
A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy Infants
Oct 10, 2026
Recruiting
A Randomized, Double-blind, Parallel Group Phase 3 Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (PERSIST CRSwNP-2)
Oct 7, 2026
Completed
A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a
Oct 7, 2026
Active, not recruiting
A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma
Oct 7, 2026
Completed
Prospective Cohort Study to Monitor the Emergence of SARS-CoV-2 Spike Viral Variants in Immunocompromised Non-hospitalized Patients Exposed to Sotrovimab in Great Britain: LUNAR Study
Oct 6, 2026
Active, not recruiting
A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)
Details
Company Info
Company Overview
$80.0B
Mkt Cap
$30.3B
Revenue
$4.2B
Cash
CEOEmma Walmsley
Founded2000
Employees70,000
HQLondon, United Kingdom
ExchangeNYSE:GSK
Websitegsk.com
LinkedInCompany Page
Therapeutic Focus
Infectious DiseaseOncologyOtherRespiratoryNeurologyGastroenterologyImmunologyHematologyMetabolic & EndocrinePsychiatryCardiovascularNephrologyDermatologyOphthalmologyMusculoskeletalRare Disease
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(2 drugs)
1
—
1
—
—
Cardiovascular(2 drugs)
Dermatology(1 drug)
—
—
—
1
—
Dermatology(1 drug)
Gastroenterology(1 drug)
—
—
—
1
—
Gastroenterology(1 drug)
Hematology(1 drug)
—
—
1
—
—
Hematology(1 drug)
Immunology(6 drugs)
1
2
—
4
—
Immunology(6 drugs)
Infectious Disease(26 drugs)
—
5
9
14
—
Infectious Disease(26 drugs)
Nephrology(3 drugs)
—
2
1
—
—
Nephrology(3 drugs)
Neurology(2 drugs)
1
—
1
—
—
Neurology(2 drugs)
Oncology(22 drugs)
9
11
7
6
—
Oncology(22 drugs)
Respiratory(7 drugs)
1
3
1
3
—
Respiratory(7 drugs)
Unknown / Other(16 drugs)
1
7
5
5
1
Unknown / Other(16 drugs)
Regulatory
Regulatory Timeline
20221 event
FDADec 2
Vilanterol — TRELEGY ELLIPTA
Application NDA209482
20239 events
FDADec 13
Cabenuva — CABENUVA KIT
Application NDA212888
FDAJul 6
Promacta — PROMACTA
Application NDA022291
FDAJun 2
Vilanterol — ANORO ELLIPTA
Application NDA203975
FDAJun 2
Vilanterol — TRELEGY ELLIPTA
Application NDA209482
FDAMay 12
Vilanterol — BREO ELLIPTA
Application NDA204275
FDAMar 9
Promacta — PROMACTA KIT
Application NDA207027
FDAMar 9
Promacta — PROMACTA
Application NDA022291
FDAFeb 27
Cabenuva — CABENUVA KIT
Application NDA212888
FDAJan 31
Sterile water — STERILE WATER FOR INJECTION
Application ANDA212735
20243 events
FDADec 27
Promacta — PROMACTA
Application NDA022291
FDASep 20
Cabenuva — CABENUVA KIT
Application NDA212888
FDAAug 12
Sterile water — STERILE WATER FOR IRRIGATION
Application ANDA216123
20257 events
FDANov 26
Cabenuva — CABENUVA KIT
Application NDA212888
FDANov 10
Sumatriptan and Naproxen sodium — SUMATRIPTAN AND NAPROXEN SODIUM
Application ANDA202803
FDANov 10
Sumatriptan and Naproxen sodium — SUMATRIPTAN AND NAPROXEN SODIUM
Application ANDA202803
FDANov 10
Sumatriptan and Naproxen sodium — SUMATRIPTAN AND NAPROXEN SODIUM
Application ANDA202803
FDAJun 6
Promacta — PROMACTA KIT
Application NDA207027
FDAJun 6
Promacta — PROMACTA
Application NDA022291
FDAApr 11
Cabenuva — CABENUVA KIT
Application NDA212888
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)